ESMO V-Learning: Targeting MET with an emphasis on NSCLC
- To understand the multi-domain structure of MET and hepatocyte growth factor, as well as their role in processes at the cell level
- To understand the MET pathway and related signalling, as well as a role of this cascade in different types of cancer
- To describe novel therapeutic agents – c-MET inhibitors, their mechanism of action and achievements from recent clinical studies in non-small cell lung cancer and other tumour types
|Title||Duration||Content||CME Points||CME Test|
|Targeting MET with an Emphasis on NSCLC||59 min.||75 slides||1||Take Test|
MET contributes to physiological processes such as embryonic development, muscular and nervous system development, homeostasis, regeneration and wound healing. MET is the only known receptor for hepatocyte growth factor (HGF). Activation of the MET receptor by HGF binding triggers a large, multistep, tightly regulated and intricated signal transduction cascade. These signalling events also culminate in initiating almost all cellular processes defining the malignant Phenotype.
The goal of this V-learning module is to provide a scientific overview of the multidomain structure of MET and HGF, milestones in MET and HGF discoveries, to show signalling cascade and subsequently triggered processes in an animated model to enhance understanding, to provide an update on dysregulation of the MET signalling pathway which occurs in a wide range of human cancers, to review selected MET inhibitors and their inhibitory targets in the MET pathway, and provide a scientific rationale on data from recent clinical studies in different tumour types, but with a special emphasis on non-small cell lung cancer.
This is the first ESMO CME module foreseen for distance-learning, which is technically empowered by video material on signalling cascade embedded in the slide presentation. Please note that the module does not end with the movie. It is part of the ESMO strategic initiative to educate medical oncologists on molecular pathways and processes which underline cancer development and progression. It was initiated by the ESMO Translational Research Working Group (TRWG), and the recently established ESMO Personalised Medicine Task Force shares the same objective. This material is produced exclusively by ESMO and the ESMO TRWG wished to show the complexity of full pathway and its targeting, and to provide an unbiased perspective on it.
From the clinical perspective this module focuses on non-small cell lung cancer, but touches also the most important findings in some other cancer types. It also features a recent article published by the presenter as a first author in the Nature Reviews Clinical Oncology. The underlining science is additionally described in the second paper published in the prestigious Nature Reviews Cancer and if you are interested in more information on the subject you can refer to these two articles, which are available for free to ESMO members through the ESMO Scientific Journal Access programme.
Please log in to myESMO and access the full articles in the My Journals area
- Peters S and Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012; 9(6): 314–326.
- Gherardi E, Birchmeier W, Birchmeier C et al . Targeting MET in cancer: rationale and progress: Nat Rev Canc 2012; 12(2): 89-103.
Without being logged-in, you will only be able to read abstracts and not a full articles.
The author has reported no conflict of interest.